



August 5, 2013

Cara Therapeutics to Present at 2013 Wedbush Securities Life Sciences Management Access Conference

SHELTON, Conn., August 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 14, 2013 at 12:45 p.m. ET in New York City.

SHELTON, Conn., August 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 14, 2013 at 12:45 p.m. ET in New York City.

About Cara Therapeutics

Cara Therapeutics is a privately-held biopharmaceutical company based in Shelton, Conn., that is focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics, including CR845, which is in development for the treatment of acute and chronic pain and pruritus. In two randomized, placebo-controlled Phase II studies, CR845 demonstrated evidence of analgesic efficacy when administered as a single intravenous dose post-operatively or when dosed both pre-operatively and post-operatively to women undergoing laparoscopic hysterectomy.

Cara has entered into separate regional licensing agreements for CR845 with Chong Kun Dang Pharmaceutical Corporation and Maruishi Pharmaceutical Company, Ltd. in the Republic of Korea and Japan, respectively. Cara's investors include: Rho Ventures, Alta Partners, Devon Park Bioventures, Ascent Biomedical Ventures, Esperante AB and MVM Partners.

For more information on the company, please visit www.caratherapeutics.com.

Contact

Derek Chalmers, President & CEO, Cara Therapeutics, 203-567-1500 Paul Cox, Stern Investor Relations, 212-362-1200